Skip to main content

Advertisement

SpringerLink
Log in

Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Ovarian cancer is the most lethal gynecological cancer due to lack of clear symptom and reliable screening biomarker in the early stage. The capability to detect the initiation of malignancy with a sensitive and effective approach is one of the most desirable goals for ovarian cancer therapy. In this study, we spearheaded noninvasive detection of ovarian cancer by salivary transcriptomic biomarkers, and evaluated the clinical utilities of discovered biomarkers using a clinical case–control study. To find salivary mRNA biomarkers, salivary transcriptomes in 11 ovarian cancer patients and 11 matched controls were profiled by Affymetrix HG-U133-Plus-2.0 array. The biomarker candidates selected from the microarray results were then subjected to clinical validation by RT-qPCR using an independent sample cohort including 21 ovarian cancer patients and 35 healthy controls. Seven downregulated mRNA biomarkers were validated. The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity. This emerging approach with high-throughput, noninvasive, and effective advantages provides a feasible means for detection of systemic cancer, and opens a new avenue for early disease detection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G (2011) Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 30:141–151

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  3. Verheijen RHM, Von Mensdorff-Pouilly S, Van Kamp GJ, Kenemans P (1999) CA125: fundamental and clinical aspects. Cancer Biol 9:117–124

    Article  CAS  Google Scholar 

  4. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC Jr, Hacker NF (2001) OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92:2837–2844

    Article  PubMed  Google Scholar 

  5. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC Jr, Zhang Z, Nicoletto MO, Donach M, Yu Y et al (2010) Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol 31:209–215

    Article  PubMed  CAS  Google Scholar 

  6. Fleischer A (eds) (1997) Ovarian cancer. In: Fleischer AC, Javitt MC, Jeffrey RB, Jones HW Clinical Gynecologic Imaging. Lippincott Williams & Wilkins, Philadelphia, pp 107

  7. Bast RC Jr (2004) Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc 115:233–248

    PubMed  Google Scholar 

  8. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC et al (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577

    Article  PubMed  CAS  Google Scholar 

  9. Tchagang AB, Tewfik AH, DeRycke MS, Skubitz KM, Skubitz AP (2008) Early detection of ovarian cancer using group biomarkers. Mol Cancer Ther 7:27–37

    Article  PubMed  CAS  Google Scholar 

  10. Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, Li L, Wang Z, Wan JC, Davuluri RV (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12:2788–2794

    Article  PubMed  CAS  Google Scholar 

  11. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J et al (2007) Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 56:3588–3600

    Article  PubMed  CAS  Google Scholar 

  12. Li Y, St John MA, Zhou X, Kim Y, Sinha U, Jordan RC, Eisele D, Abemayor E, Elashoff D, Park NH et al (2004) Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 10:8442–8450

    Article  PubMed  CAS  Google Scholar 

  13. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15:5473–5477

    Article  PubMed  CAS  Google Scholar 

  14. Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT, Nagalla SR (2009) Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 8:239–245

    Article  PubMed  CAS  Google Scholar 

  15. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, Chia D, Wong DT (2010) Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 138:949–957

    Article  PubMed  CAS  Google Scholar 

  16. Zhang L, Xiao H, Karlan S, Zhou H, Gross J, Elashoff D, Akin D, Yan X, Chia D, Karlan B et al (2010) Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 5:e15573

    Article  PubMed  CAS  Google Scholar 

  17. Chen DX, Schwartz PE, Li FQ (1990) Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 75:701–704

    PubMed  CAS  Google Scholar 

  18. Boucaud M, Pinguet F, Poujol S, Romieu G, Cupissol D, Astre C, Culine S, Bressolle F (2001) Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. Eur J Cancer 37:2357–2364

    Article  PubMed  CAS  Google Scholar 

  19. Ballantyne J (2007) Validity of messenger RNA expression analyses of human saliva. Clin Cancer Res 13:1350–1351

    Article  PubMed  Google Scholar 

  20. Li Y, Zhou X, St John MA, Wong DT (2004) RNA profiling of cell-free saliva using microarray technology. J Dent Res 83:199–203

    Article  PubMed  CAS  Google Scholar 

  21. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55:611–622

    Article  PubMed  CAS  Google Scholar 

  22. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561–577

    PubMed  CAS  Google Scholar 

  23. Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, Andersen JS, Schumacher V, Royer-Pokora B, Mann M et al (2004) BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol 24:537–549

    Article  PubMed  CAS  Google Scholar 

  24. Li Y, Elashoff D, Oh M, Sinha U, St John MA, Zhou X, Abemayor E, Wong DT (2006) Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol 24:1754–1760

    Article  PubMed  CAS  Google Scholar 

  25. Arlt A, Schäfer H (2011) Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. Eur J Cell Biol 90:545–552

    Article  PubMed  CAS  Google Scholar 

  26. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D et al (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71:3162–3172

    Article  PubMed  CAS  Google Scholar 

  27. Hernádi Z, Molnár V, Juhász B, Pólka R, Margitai B (1992) Predictive value of the tumor marker combination CA-125 and beta-2-microglobulin in ovarian cancer. Zentralbl Gynakol 114:6–9

    PubMed  Google Scholar 

  28. Yang HS, Li Y, Deng HX, Peng F (2009) Identification of beta2-microglobulin as a potential target for ovarian cancer. Cancer Biol Ther 8:2323–2328

    Article  PubMed  CAS  Google Scholar 

  29. Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT (2004) Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol 95:672–679

    Article  PubMed  CAS  Google Scholar 

  30. Cheng L, Lu W, Kulkarni B, Pejovic T, Yan X, Chiang JH, Hood L, Odunsi K, Lin B (2010) Analysis of chemotherapy response programs in ovarian cancers by the next-generation sequencing technologies. Gynecol Oncol 117:159–169

    Article  PubMed  CAS  Google Scholar 

  31. Landman AD, Sanford LM, Howland BE, Dawes C, Pritchard ET (1976) Testosterone in human saliva. Experientia 32:940–941

    Article  PubMed  CAS  Google Scholar 

  32. Hammond GL, Langley MS (1986) Identification and measurement of sex hormone binding globulin (SHBG) and corticosteroid binding globulin (CBG) in human saliva. Acta Endocrinol (Copenh) 112:603–608

    CAS  Google Scholar 

  33. Kubagawa H, Bertoli LF, Barton JC, Koopman WJ, Mestecky J, Cooper MD (1987) Analysis of paraprotein transport into saliva by using anti-idiotype antibodies. J Immunol 138:435–439

    PubMed  CAS  Google Scholar 

  34. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, Wolinsky LE, Farrell J, Eibl G, Wong DT (2009) Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One 4:e5875

    Article  PubMed  Google Scholar 

  35. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100:1432–1438

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by National Research Foundation of Korean government (KRF-2008-314-E00121 and 2011–0010286).

Disclosure statement

David T. Wong is co-founder of RNAmeTRIX Inc., a molecular diagnostic company.

Author information

Authors and Affiliations

  1. Graduate Institute of Biomedical Engineering, National Central University, Jhongli City, 32001, Taiwan, Republic of China

    Yu-Hsiang Lee

  2. UCLA School of Dentistry and Dental Research Institute, 73-017 CHS, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA

    Yu-Hsiang Lee, Hui Zhou & David T. Wong

  3. Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

    David T. Wong

  4. Molecular Biology Institute, Los Angeles, CA, USA

    David T. Wong

  5. Division of Head and Neck Surgery/Otolaryngology, David Geffen School of Medicine, Los Angeles, CA, USA

    David T. Wong

  6. Henry Samuel School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA, USA

    David T. Wong

  7. Department of Obstetrics and Gynecology, Gangnam Biomedical Research Center Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

    Jae Hoon Kim

  8. Tissue Array Research Program, Laboratory of Pathology, National Cancer Institute, Bethesda, MA, USA

    Bo Wook Kim

Authors
  1. Yu-Hsiang Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jae Hoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bo Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David T. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David T. Wong.

Additional information

Yu-Hsiang Lee and Jae Hoon Kim contributed equally to this manuscript.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 334 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, YH., Kim, J.H., Zhou, H. et al. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma. J Mol Med 90, 427–434 (2012). https://doi.org/10.1007/s00109-011-0829-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-011-0829-0

Keywords

Search

Navigation